Business
Marvel Commences Final Study Required Prior to Initiating Human Trials
Calgary, Alberta--(Newsfile Corp. - March 21, 2023) - Marvel Biosciences Corp. (TSXV: MRVL) and...
About this update from Marvel Biosciences Corp
[{"type":"text","content":"Marvel Commences Final Study Required Prior to Initiating Human TrialsCalgary, Alberta--(Newsfile Corp. - March 21, 2023) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the \"Company\" or \"Marvel\"), is pleased to announce that it has initiated the 4-week good laboratory practice (GLP) FDA investigational new drug (IND) enabling dose-ranging dog studies for its lead drug candidate MB-204.\"This dog study is the last of the two key primary animal studies we need to complete before entering phase 1 human clinical testing of our lead asset - MB-204,\" said Dr. Mark Williams, Chief Science Officer of Marvel Biosciences. \"We are now planning our Phase 1 human trials, likely to be conducted in Australia upon the successful conclusion of this study and the previously commenced 4-week rat GLP study.\"\"We look forward to the completion of the rat and dog GLP studies of MB-204, and entering human trials, prior to the end of Q3 2023,\" said Rod Matheson, CEO of Marvel Biosciences. \"We believe the profile of MB-204 is well-suited to address our primary markets, specifically depression and Alzheimer's disease. Owing to the immediate effect of the compound, we are confident that it will show the active effects early on in our clinical program.\" In the United States, it is estimated that one in ten senior citizens over the age of 65 suffer from dementia. MB-204 is a novel solution to Alzheimer's that has similar properties to the Food and Drug Administration-approved drug, Istradefylline. MB-204 has, through the Company's studies, proven to be more effective and longer lasting than Istradefylline in pre-clinical studies. MB-204 is a fluorinated derivative of the U.S. FDA-approved adenosine A2a receptor antagonist, Istradefylline. Both Istradefylline and MB-204 are highly active derivatives of caffeine, the most widely consumed psychoactive drug in the world. Caffeine consumption has been associated with a reduced risk of developing Parkinson's disease and Alzheimer's disease, as well as leading to an improved ability to concentrate. About Marvel Biosciences Corp.Marvel Biosciences Corp., and its wholly owned subsidiary, Marvel Biotechnology Inc., is a Calgary-based pre-clinical stage pharmaceutical development biotechnology company that utilizes a \"drug redevelopment\" app...